Aims: A recombinant humanized anti-cocaine monoclonal antibody (mAb), h2E2, is at an advanced stage of preclinical development as an immunotherapy for cocaine abuse. It is hypothesized that h2E2 binds to and sequesters cocaine in the blood. Main methods: A three-compartment model of the effects of h2E2 on cocaine's distribution was constructed. The model assumes that h2E2 binds to cocaine and that the h2E2-cocaine complex does not enter the brain but distributes between the central and peripheral compartments. Free cocaine is eliminated from both the central and peripheral compartments, and h2E2 and the h2E2-cocaine complex are eliminated from the central compartment only. This model was tested against a new dataset measuring cocaine concentrations in the brain and plasma over 1 h in the presence and absence of h2E2. Key findings: The mAb significantly increased plasma cocaine concentrations with a concomitant significant decrease in brain concentration. Plasma concentrations declined over the 1-hour sampling period in both groups. With a set of parameters within reasonable physiological ranges, the three-compartment model was able to qualitatively and quantitatively simulate the increased plasma concentration in the presence of the antibody and the decreased peak brain concentration in the presence of antibody. Importantly, the model explained the decline in plasma concentrations over time as distribution of the cocaine-h2E2 complex into a peripheral compartment. Significance: This model will facilitate the targeting of ideal mAb PK/PD properties thus accelerating the identification of lead candidate anti-drug mAbs.
Introduction
Immunotherapy represents a promising potential treatment for substance use disorders [1] . This includes anti-drug monoclonal antibodies (mAbs), which are hypothesized to bind to these drugs of abuse and prevent their entry into the brain, thus nullifying the central nervous system (CNS) effects of these drugs. This approach has shown success in preclinical animal studies of an anti-methamphetamine mAb [2] , which has advanced into clinical trials [3] . A hybridoma-derived anticocaine mAb with a human heavy chain and a murine light chain (designated 2E2) and the reengineered recombinant version of this anti-cocaine mAb, designated h2E2, have also been developed. The mAb h2E2 has high affinity and selectivity for cocaine over its inactive metabolites [4, 5] and has a long plasma half-life in both rats and mice. In rats, the recombinant humanized mAb has been shown to decrease brain concentrations of cocaine [4] and prevent cocaine-induced priming of self-administration behavior [6] . In mice, h2E2 can antagonize the distribution of cocaine's active metabolite, cocaethylene, into the brain [7] . However, the effects of h2E2 on cocaine's distribution to the brain in mice has never been reported. Since mice are a common model species, it is important to determine these effects in this species.
Considerable effort has been dedicated to developing anti-drug mAbs with ideal binding and pharmacokinetic profiles. Generally, it has been assumed that mAbs with high binding affinity for their target drug, selectivity over inactive metabolites and with long biological pharmacokinetic half-lives are superior. The mAb should also be able to rapidly alter the distribution and pharmacokinetics of the target drug. However, many of these assumptions have been called into question. For example, it is speculated that high selectivity of the humanized anti-cocaine mAb h2E2 over the major inactive metabolite benzoylecgonine may not be ideal, and may exacerbate the increase in cocaine consumption that is observed after the mAb has been surmounted [6] . Extensive study of anti-methamphetamine mAbs with varying pharmacological profiles has also revealed that in vitro affinities and in vivo pharmacokinetic half-life are not always predictive of the magnitude and duration of action of these antibodies [8] . This underscores the need for in vivo animal efficacy testing of anti-drug mAbs. However, these studies require large quantities of purified mAb and are time consuming and costly to conduct. Alternatively, a mathematical model of the effects of an anti-drug antibody on its ability to alter the distribution and pharmacokinetics of the target drug could be used to efficiently provide valuable information in determining the ideal characteristics of an anti-drug mAb.
The goal of the current study was to develop a pharmacokinetic model of the interaction between the anti-cocaine mAb h2E2 and cocaine. This model is validated against a new data set determining the effects of h2E2 on cocaine's distribution to the brain in mice. This model will provide valuable information on how the pharmacological properties of the mAb will likely effect in vivo efficacy as measured by cocaine distribution to the brain, leading to more targeted design of future antidrug mAbs for the treatment of overdose and substance use disorders.
Methods

Effects of h2E2 on cocaine distribution in mice
All studies were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals [9] and under a protocol approved by the Institutional Animal Care and Use Committee at the University of Cincinnati. Adult male jugular vein catheterized Swiss-Webster mice (19-22 g) were purchased from Taconic Farms. Mice were housed individually on a 14/10-hour light/dark schedule with unrestricted access to food and water. Mice were injected with h2E2 (120 mg/kg) or vehicle (PBS) i.v. One hour later, mice were injected with an equimolar dose of cocaine HCl (0.56 mg/kg) i.v. At 45 s, 1.5, 3, 5, 10, 20, 40 and 60 min following cocaine injection, 3 mice per time point were anesthetized and decapitated and trunk blood was collected and spun to separate plasma. Brains were removed and immediately placed on dry ice. At 3 min prior to decapitation mice were anesthetized with sodium pentobarbital (45 mg/kg i.p.). All samples were stored at − 20°C. Cocaine was quantified using gaschromatography/mass-spectrometry using methods reported previously [10] .
Materials
Cocaine HCl was provided by the Research Triangle Institute under the National Institute on Drug Abuse Drug Supply Program. Deuterated cocaine-D3 (0.1 mg/mL in acetonitrile), was used as an internal standard, unlabeled cocaine (1 mg/mL in acetonitrile), used to generate a standard curve, and the derivatizing reagent N,O-bis(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane were purchased from Cerilliant. Recombinant h2E2 was produced from stably transfected CHO-cell lines by Catalent Pharmasolutions using their proprietary GPEx technology [11] .
Model construction
A diagrammatic depiction of the model is shown in Fig. 1 . In summary, a three-compartment model of the effects of h2E2 on cocaine's distribution was constructed. The three compartments represent the central compartment, or blood and well-perfused organs, the peripheral compartment, and the brain compartment. The model assumes that h2E2 binds to cocaine and that the h2E2-cocaine complex does not enter the brain but is able to distribute between the central and the peripheral compartments. This assumption is based on the knowledge that antibodies are unable to cross the blood-brain-barrier, whereas lipophilic small molecular weight drugs such as cocaine can [1] . It was assumed that h2E2 can enter peripheral compartments based on the distribution phase observed in pharmacokinetic studies in mice [12] . Since cocaine is much smaller than h2E2 and presumably interacts only with the binding site, h2E2 is assumed to be eliminated and distributed at the same rates whether bound or unbound, h2E2 is eliminated only from the central compartment, while cocaine is eliminated from both compartments. Initial values for central cocaine and antibody were set equimolar (since the experimental doses were equimolar) at the experimental Cmax in the presence of h2E2. This value was also used in the control simulations, as the Cmax at time zero should be equal for both vehicle and h2E2-treated groups since the same dose of cocaine was injected i.v. in both groups. Terms for the relative volumes of the compartments (C/B and C/P in the equations) were used to convert data from amounts to concentrations when the molecules travel between different compartments. Brain tissue was assumed to have a density of 1 g/mL for analysis of the experimental data. The system of ordinary differential equations (ODEs) describing this system is shown below.
A wire diagram of a three-compartment model of h2E2 binding to cocaine. kon and koff represent binding constants. ck21, ck12, ck13, ck31, ck30, and ck10 represent pharmacokinetic rate constants for cocaine, ak13, ak31 and ak10 represent pharmacokinetic rate constants for the antibody h2E2. The ak10, ck10 and ck30 terms represent the species leaving the system. 
Determination of parameter values and parameter sweep
An original set of parameters was determined by visually fitting the simulations to the data. In order to sample the parameter space, a set of 120,000 random values within a 10-fold range on either side of the original values were generated. 12,000 simulations were then executed, where each simulation selected a random value for each parameter. The total difference between the simulation values and the experimental values in all four data sets (plasma and brain concentrations in vehicle and h2E2 treated animals) was used to estimate goodness of fit.
Phase plane analysis
In order to carry out phase plane analysis, the model is simplified to two differential equations:
with:
x ¼ free cocaine in central compartment
where TC = total cocaine, TA = total antibody, by assuming the following:
1) Degradations are much slower than antibody distribution as well as cocaine-h2E2 complex association and dissociation; 2) High affinity between antibody and cocaine;
3) The concentration of total cocaine is higher than the concentration of total antibody, therefore there is free cocaine in the system.
These two equations were used to compute the phase plane.
Sensitivity analysis
To determine the relative impact of each of the parameters on the output of the model, a sensitivity analysis was performed. Peak brain concentrations were chosen as a single value output of the model, as this has been shown to be a key determinant of the probability of reinstatement of self-administration behavior in animals, and therefore may be a predictor of relapse [13] . Each parameter value was both increased and decreased by 10-fold, and the peak brain concentrations yielded in both vehicle and h2E2 simulations were recorded.
Software
Wolfram Mathematica V.10 was used to develop the model and the Manipulate function was used as a graphical user interface to determine parameter values with a good fit to the data. Random iterations and sensitivity analysis were executed using Python's SciPy library. Phase-plane analysis was carried out with Xppaut (http://www.math.pitt.edu/ bard/xpp/xpp.html) and plotted with MatLab (The MathWorks Inc., Natick, MA, 2015).
Results
Experimental
Mice were treated with the mAb h2E2 or vehicle, then injected with an equimolar dose of cocaine. Blood and brain samples were taken at varying time-points from 45 s to 1 h. Mean ± SEM peak plasma concentrations in controls were significantly increased (p = 0.003, t-test) from 593 ± 71.2 nmol/L in control mice to 14,026 ± 3734 nmol/L in treated animals. The area under the time-concentration curve (AUC) was increased 61-fold from 218,557 nmol·s·L − 1 in controls to 13,329,523 nmol·s·L −1 in treated animals ( Fig. 2A) . Plasma concentrations in both groups declined over the 1-hour sampling period. In contrast, peak brain concentrations were significantly lower (p = 0.01, t-test) in the presence of the antibody (4146 ± 448 nmol/L in vehicle treated mice compared to 650 ± 344 in h2E2-treated mice). The AUC was also decreased 85% from 3,402,451 nmol·s·L − 1 to 495,205 nmol·s·L −1 in the presence of h2E2 (Fig. 2B ).
Computational
A three-compartment model was constructed (Fig. 1) . The model was able to reasonably capture all data ( Fig. 2A and B) . Parameter values that produced these simulations are shown in Table 1 . 12,000 random simulations with parameter values varying from 10% to 10-fold of the values in Table 1 were run. Out of these 12,000, only two yielded smaller total distances between the experimental data and simulated data (0.6% and 7% overall improvements). However, all improvement was in the fit to the brain data, at the cost of poorer fits to the plasma data, including systematic deviation from the data at the lower concentrations. Since the plasma data is more trustworthy given the experimental setting, these "improved" simulations were not accepted and the original parameter values were maintained.
A phase plane analysis where the system was simplified to two variables (cocaine in central compartment and cocaine in the brain) showed a linear relationship between cocaine in the central compartment and cocaine in the brain, where (assuming all positive constants) increasing antibody always decreased brain concentrations of cocaine. This highlights the robustness of the model. For example, note that the central/brain volume ratio (C/B) has an effect on the quantitative features of the system, however, it does not change the shape of the balance curves, and hence does not affect the qualitative features of the system (Fig. 3) .
The model predicts that almost all of the cocaine seen in the plasma in the presence of h2E2 is bound (antibody-cocaine complex); AUC = 579,481 nmol·s·L . In the presence of the antibody, most of the peripheral cocaine was bound (AUC = 15,714,775 nmol·s·L −1 for bound, and 579,481 nmol·s·L − 1 for free) (Fig. 4B) . As an assumption of the model, all cocaine in the brain was free in both data sets. A sensitivity analysis was performed, where parameter values were both increased and decreased 10-fold and the effect on peak brain concentration was observed. In rank order, the system was sensitive to (largest to smallest change) ck12 (Fig. 5 ).
Discussion
The ability of the anti-cocaine mAb h2E2 to prevent cocaine's entry into the brain in mice is consistent with all previous reports [4, 7, 10] . Our model was able to adequately simulate these results, including cocaine concentrations in the brain and plasma of mice in the presence and absence of the anti-cocaine mAb h2E2 (Fig. 2 ). Though this model was validated against a dataset using mice as a model species, parameter values could be readily adjusted to allow for it to apply to other species, such as rats and eventually humans. This indicates that the model proposed has physiological relevance, and that the parameter values used to generate the simulations are reasonable. The difference between the data and simulated values observed in the brain in the presence of the antibody could be due to blood in the brain. The data is generated using whole homogenized brain, so some blood will be included in the sample. Since, in the presence of h2E2, plasma levels of cocaine are highly elevated, it is possible that the measured values are artificially high. This could account for the observed differences between the experimental observations and simulations. Both the distribution and elimination constants were much smaller for h2E2 than for cocaine, which is consistent with h2E2's much larger molecular weight (303 Da for cocaine, about 150,000 Da for h2E2), its slower distribution (0.5 min for cocaine, 13.5 h for h2E2) and slower elimination (16 min for cocaine, 7.8 days for h2E2) half-lives reported in rats [4] . Overall, this model predicts that increases in antibody concentration will always result in decreased brain concentrations of cocaine. Though, in cases when the cocaine to mAb ratio is very high, these differences may be very small and of little physiological relevance. The magnitude of this effect will be determined by the concentration of free cocaine in the central compartment, which is a function of the intercompartmental rate constants and the affinity of the antibody for the drug. Consequently, the model should be able to predict how much drug is able to enter the brain under all circumstances. This prediction is robust despite the fact that many parameter values are unknown or imprecise. For example, the C/B volume ratio will not change the shapes of the balance curves, and hence will not change the conclusions of the model (Fig. 3) . This is because cocaine concentration in the brain is a direct function of free cocaine in the plasma, which is drastically lowered by h2E2. This is consistent with the finding that increasing the dose of the murine 2E2 decreased brain concentrations of cocaine following a single dose of cocaine [10] . This predicts that increasing antibody concentrations would be a robust strategy to decrease drug penetration into the brain for target drugs that have a large range of PK/PD properties. However, in clinical trials of a cocaine vaccine, high antibody titers were not associated with decreased urine samples positive for cocaine, where positive urine samples were used as a measure of efficacy [14] . More work is needed to explain the apparent discrepancies between the pre-clinical and modeling results and the clinical trials of a cocaine vaccine. Modeling of cocaine self-administration behavior in the presence of an antibody may be informative.
It should be noted that it is technically very difficult to measure how much cocaine is free or bound in vivo. According to this model, the large observed increase in cocaine concentrations in the plasma is mainly due to an increase in bound cocaine, not free (Fig. 4A) . Therefore, one would expect that the enzymatic degradation of cocaine would be slowed Table 1. since h2E2 would restrict access of cocaine to enzymes. However, cocaine appears to leave the plasma at approximately the same rate in the presence and absence of h2E2 in rats [4] . The same was observed for cocaethylene disappearance in mice [7] and the present study also observed the same effect on cocaine disappearance in the presence of h2E2 in mice. It has been previously speculated that this disappearance of cocaine from plasma actually represented a delayed distribution into the peripheral compartments, instead of an unchanged rate of elimination of the drug [7] . The current model supports this hypothesis. This model predicts a relatively large accumulation of cocaine in the peripheral compartment in the presence of h2E2. Throughout the hour, peripheral concentrations of cocaine continue to accumulate, while in control simulations, the peak was reached almost immediately (Fig.  4B) . Therefore, the observed disappearance of cocaine out of the plasma could be accounted for by distribution of h2E2-bound cocaine into peripheral compartments. Additionally, since most of the cocaine is bound, h2E2 might be expected to ameliorate any peripheral effects of cocaine in addition to the central effects of cocaine. If so, anti-cocaine mAbs may be useful to treat all toxic effects of cocaine at any site of action within the body.
This model also predicts that peak brain concentrations were most affected by the rate of distribution into the brain (ck12). This implies that drugs that less rapidly enter the brain will be more amenable to antibody therapy. However, the properties of the target drug are usually out of the control of the investigator. More useful, the system was also extremely sensitive to changes in both the kon and koff binding constants. Affinity for a drug can be experimentally modified using point mutations, such as what was done for an anti-methamphetamine antibody [15] . Importantly, peak brain concentrations were equally sensitive to both values, meaning that alterations to either value (kon or koff) will have equal impact on effectiveness because the ratio between the two parameters (Kd) is an important determining factor for effectiveness. Interestingly, in order to provide an improved fit of the model to the experimental data, both the kon and koff values yielded by the model are much more rapid than is generally assumed. Though the kon used is outside of the range that would be expected from a diffusion-based value, it is not unreasonable if electrostatic interactions are occurring. For example, it has been shown that kon rates for antibody-antigen interactions can be increased by the introduction of charged residues into the framework region of the antibody [16] . Because h2E2 likely has lysine residues at the binding region [17] , it is possible that these charged residues are causing electrostatic interactions, leading to an unusually high kon rate. If so, this is overall favorable, since it means that the antibody would be able to more rapidly sequester cocaine in the plasma. The resulting Kd of h2E2 for cocaine from the kon and koff values generated by this model is similar to what was previously reported (2.2 nM) [12] .
Conclusions
In conclusion, we have presented a mathematical model that accurately simulates the effects of an anti-cocaine antibody on cocaine's pharmacokinetics in both the plasma and the brain. This model has already generated testable hypotheses about antibody-drug interactions both in vivo and in vitro. This modeling approach will be a useful tool for probing drug-antibody interactions and accelerating the development of future anti-drug antibodies.
